Updates to your 2027 Prescription Drug List for Exchange plans

We are updating our 2027 Exchange Prescription Drug List (PDL). When making changes, we consider a medication's overall value, which is based on factors such as effectiveness, safety, cost and the availability of alternative medications to treat the same or similar medical condition.

Prescription Drug List (PDL) update: Effective Jan. 1, 2027

- **Prior authorization (PA):** Requires your healthcare provider to provide information about why you are taking a medication before your plan can decide how it may be covered.
- **Quantity limit (QL):** The largest quantity of medication covered per copayment or in a defined period of time.

Medication	Type of change	Effective date	Coverage rules or limits
Adalimumab-ADAZ	Removed from PDL	1/1/2027	N/A
Adalimumab-FKJP	Removed from PDL	1/1/2027	N/A
Wezlana	Removed from PDL	1/1/2027	N/A
Adalimumab-AACF	Added to PDL	10/15/2026	PA and QL
Adalimumab-AATY	Added to PDL	10/15/2026	PA and QL
Imuldosa	Added to PDL	10/15/2026	PA and QL
Pyzchiva	Added to PDL	10/15/2026	PA and QL
Starjemza	Added to PDL	10/15/2026	PA and QL
Steqeyma	Added to PDL	10/15/2026	PA and QL
Ustekinumab-AAUZ	Added to PDL	10/15/2026	PA and QL
Yusimry	Added to PDL	10/15/2026	PA and QL
Oxycontin	Tier 2 to Tier 3	1/1/2027	N/A